Abstract | INTRODUCTION: AREAS COVERED: This review focuses on the biologic rationales of IMiDs and the clinical results supporting their use in MF. It includes data on the new IMiD, pomalidomide and also explores the possible utility of combining IMiDs with other agents. A PubMed search of articles related to IMiDs and myelofibrosis were conducted. Relevant studies and clinical studies with sample size of > 15 were included. EXPERT OPINION:
|
Authors | Ali Tabarroki, Ramon V Tiu |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 8
Pg. 1141-54
(Aug 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22668122
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Clinical Trials as Topic
- Drug Therapy, Combination
- Humans
- Immunologic Factors
(therapeutic use)
- Primary Myelofibrosis
(drug therapy)
|